Clinical Trials
4
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
Phase 1
Recruiting
- Conditions
- PainOsteoarthritisChronic PainDorsal Root GanglionNav 1.7Post Herpetic NeuralgiaNeuropathic Pain
- Interventions
- Drug: iN1011-N17 HCl Capsule (Part 3)Drug: Placebo Capsule (Part 3)Drug: Placebo Capsule (Part 1)Drug: iN1011-N17 HCl Suspension (Part 1)Drug: iN1011-N17 HCl Capsule (Part 1)Drug: iN1011-N17 HCl Capsule (Part 2)Drug: iN1011-N17 Mesylate Capsule (Part 2)Drug: iN1011-N17 Mesylate Capsule (Part 3)
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- iN Therapeutics Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT06218784
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
Phase 1
Completed
- Conditions
- PainChronic PainPost Herpetic NeuralgiaOsteoarthritisNeuropathic PainNav 1.7
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- iN Therapeutics Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT05496205
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
News
No news found